Announcement Follows the Recent Appointment of Denham Capital Founder Stuart D. Porter — a Three-Decade Energy and Infrastructure Investor — to the Company's Board of Directors

BOCA RATON, FLA, June 03, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) (the "Company"), today announced that it has entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $16,566,027 of shares of common stock and pre-funded warrants at an offering price of (i) $6.31 per share of common stock, and (ii) $0.0001 per pre-funded warrant. The entire transaction was priced at the market under Nasdaq rules. The financing materially strengthens the Company's balance sheet and provides additional flexibility to pursue its strategic priorities.

The offering consisted of the sale of 2,625,362 shares of common stock and pre-funded warrants, each pre-funded warrant entitling the holder to purchase one share of common stock (and the common stock issuable from time to time upon exercise of such pre-funded warrants). The public offering price is $6.31 per share of common stock (or $6.3099 for each pre-funded warrant, which is equal to the public offering price per common share sold in the offering minus an exercise price of $0.0001 per pre-funded warrant). The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full.

Aggregate gross proceeds to the Company are expected to be approximately $16,566,027. The transaction is expected to close on or about June 3, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering, together with its existing cash, for general corporate purposes, working capital, and to support the Company's strategic initiatives.